Michael F. Press, Ivonne Villalobos, Angela Santiago, Roberta Guzman, Monica Cervantes, Armen Gasparyan, Anaamika Campeau,Yanling Ma, Denice D. Tsao-Wei, and Susan Groshen (2016) Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice. Archives of Pathology & Laboratory Medicine In-Press.
Early Online Release
Michael F. Press , MD, PhD; Ivonne Villalobos , MHA; Angela Santiago , BS; Roberta Guzman ; Monica Cervantes , BA; Armen Gasparyan ; Anaamika Campeau , BA; Yanling Ma , MD; Denice D. Tsao-Wei , MS; Susan Groshen , PhD
From the Departments of Pathology (Drs Press and Ma; Mss Villalobos, Santiago, Guzman, Cervantes, and Campeau; and Mr Gasparyan) and Preventive Medicine (Ms Tsao-Wei and Dr Groshen), Norris Comprehensive Cancer Center, University of Southern California, Los Angeles.
Context.—Evaluation of HER2 gene amplification by fluorescence in situ hybridization (FISH) was changed by recent American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines.
Objective.—To determine frequencies and assess patterns of HER2 protein expression for each ASCO-CAP guideline FISH category among 7526 breast cancers accrued to our consultation practice.
Design.—We retrospectively reevaluated the HER2 FISH status of breast cancers in our consultation practice according to ASCO-CAP FISH guidelines, and documented HER2 protein levels in each category.
Results.—According to new guidelines, 17.7% of our consultation breast cancers were “ISH-positive” with HER2:CEP17 FISH ratios ≥2.0 and average HER2 gene copies per cell ≥4.0 (group 1); 0.4% were “ISH-positive” with ratios ≥2.0 and average copies <4.0 (group 2); 0.6% were “ISH-positive” with ratios <2.0 and average copies ≥6.0 (group 3); 4.6% were “ISH-equivocal” with ratios <2.0 and average copies ≥4.0 and <6.0 (group 4); and 76.7% were “ISH-negative” with ratios <2.0 and average copies <4.0 (group 5). However, only groups 1 (HER2 amplified) and 5 (HER2 not amplified) agreed with our previously reported status, and only these groups demonstrated the expected immunohistochemistry status, overexpression and low expression, respectively. Groups 2 and 4 breast cancers lacked overexpression, whereas group 3 was not significantly associated with either increased or decreased HER2 expression.
Conclusions.—Although the status of approximately 95% of our cases (groups 1 and 5) is not affected by the new guidelines, those of the other 5% (groups 2–4) conflict with previous HER2 gene amplification status and with HER2 status by immunohistochemistry.